Skip to main content
. 2020 Jun 16;17:76. doi: 10.1186/s12985-020-01355-5

Table 4.

Performance of the GB kit in the presence of interfering compounds

Specimen Interfering compound mean COI ± std. Dev. p-value
Serum TG (−) 3.65 ± 0.60 0.87
TG (+) 3.59 ± 0.09
BL (−) 2.95 ± 0.83 0.77
BL (+) 2.75 ± 0.67
HB (−) 3.85 ± 0.38 0.62
HB (+) 3.68 ± 0.40
HAMA (−) 3.60 ± 0.16 0.43
HAMA (+) 3.80 ± 0.35
MAPC (−) 3.26 ± 0.49 0.20
MAPC (+) 3.89 ± 0.52
EDTA-treated plasma TG (−) 4.09 ± 0.60 0.24
TG (+) 3.57 ± 0.23
BL (−) 3.65 ± 0.84 0.48
BL (+) 3.24 ± 0.39
HB (−) 4.59 ± 0.26 0.03
HB (+) 3.90 ± 0.26
HAMA (−) 4.67 ± 0.27 0.23
HAMA (+) 4.43 ± 0.11
MAPC (−) 4.09 ± 0.09 0.01
MAPC (+) 5.02 ± 0.30

TG triglyceride, BL bilirubin, HB hemoglobin, HAMA human anti-mouse antibody plasma, MAPC multi-analyte positive control (SeraCare Accurun Series 2700)